RGNX Stock Analysis: Regenxbio | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 720m USD | 12M Return: 30.1% | US75901B1070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.1M
Qual. Beats: 1
Rev. Trend: 63.5%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
REGENXBIO Inc. (RGNX) is a U.S.-based, clinical-stage biotechnology company developing gene therapies that use its proprietary NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system, to deliver functional genes to cells with genetic defects. Its pipeline includes ABBV-RGX-314 for wet age-related macular degeneration and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, RGX-121 for mucopolysaccharidosis type II (Hunter syndrome), and RGX-111 for mucopolysaccharidosis type I.
The company is headquartered in Rockville, Maryland, was incorporated in 2008, and operates a dual business model: it develops internal gene therapy candidates while also licensing its NAV platform to other biotech and pharmaceutical partners. Notable collaborations include a development and license agreement with AbbVie for ABBV-RGX-314 and a partnership with Nippon Shinyaku for RGX-121 and RGX-111 outside the United States. As a clinical-stage biotech, REGENXBIO is not yet generating commercial product revenue, making collaboration income, milestone payments, and capital markets funding key financial drivers typical of the sector.
- ABBV-RGX-314 wet AMD pivotal trial data readout approaches
- AbbVie collaboration milestones critical to extending cash runway
- Duchenne RGX-202 gene therapy competes against Sareptas Elevidys
| Net Income: -196.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.65 > 0.02 and ΔFCF/TA -48.97 > 1.0 |
| NWC/Revenue: 88.00% < 20% (prev 163.2%; Δ -75.19% < -1%) |
| CFO/TA -0.64 > 3% & CFO -246.7m > Net Income -196.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.0m) vs 12m ago 2.98% < -2% |
| Gross Margin: 54.22% > 18% (prev 79.94%; Δ -25.71% > 0.5%) |
| Asset Turnover: 36.06% > 50% (prev 26.81%; Δ 9.25% > 0%) |
| Interest Coverage Ratio: -3.68 > 6 (EBIT TTM -154.5m / Interest Expense TTM 41.9m) |
| A: 0.40 (Total Current Assets 236.2m - Total Current Liabilities 82.6m) / Total Assets 386.6m |
| B: -3.09 (Retained Earnings -1.19b / Total Assets 386.6m) |
| C: -0.32 (EBIT TTM -154.5m / Avg Total Assets 483.8m) |
| D: 0.23 (Book Value of Equity 71.8m / Total Liabilities 314.9m) |
| Altman-Z'' = -9.36 = D |
| DSRI: 3.0 (Receivables 106.8m/21.5m, Revenue 174.5m/155.8m) |
| GMI: 1.47 (GM 79.94% / 54.22%) |
| AQI: 0.27 (AQ_t 0.02 / AQ_t-1 0.08) |
| SGI: 1.12 (Revenue 174.5m / 155.8m) |
| TATA: 0.13 (NI -196.4m - CFO -246.7m) / TA 386.6m) |
| Beneish M = -1.28 (Cap -4..+1) = D |
As of August 18, 2026, the stock is trading at USD 11.33 with a total of 1,029,340 shares traded. Over the past week, the price has changed by +8.73%, over one month by +14.56%, over three months by +100.53% and over the past year by +30.08%.
Current recommended Stop Loss: 10.30 (which is 9.1% or 1.3 ATR below the current price).
Regenxbio has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy RGNX.
- StrongBuy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.8 | 101.2% |
P/S = 4.1277
P/B = 9.5849
P/EG = 0.26
Revenue TTM = 174.5m USD
EBIT TTM = -154.5m USD
EBITDA TTM = -139.1m USD
Long Term Debt = 209.0m USD (estimated: total debt 250.5m - short term 41.5m)
Short Term Debt = 41.5m USD (from shortTermDebt, last quarter)
Debt = 319.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 69.0m
Net Debt = 213.9m USD (calculated: Debt 319.4m - CCE 105.5m)
Enterprise Value = 934.1m USD (720.2m + Debt 319.4m - CCE 105.5m)
Interest Coverage Ratio = -3.68 (Ebit TTM -154.5m / Interest Expense TTM 41.9m)
EV/FCF = -3.74x (Enterprise Value 934.1m / FCF TTM -249.7m)
FCF Yield = -26.73% (FCF TTM -249.7m / Enterprise Value 934.1m)
FCF Margin = -143.1% (FCF TTM -249.7m / Revenue TTM 174.5m)
Net Margin = -112.6% (Net Income TTM -196.4m / Revenue TTM 174.5m)
Gross Margin = 54.22% ((Revenue TTM 174.5m - Cost of Revenue TTM 79.9m) / Revenue TTM)
Gross Margin QoQ = none% (prev -73.22%)
Tobins Q-Ratio = 2.42 (Enterprise Value 934.1m / Total Assets 386.6m)
Interest Expense / Debt = 13.13% (Interest Expense 41.9m / Debt 319.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -122.0m (EBIT -154.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 236.2m / Total Current Liabilities 82.6m)
Debt / Equity = 4.45 (Debt 319.4m / totalStockholderEquity, last quarter 71.8m)
Debt / EBITDA = -1.54 (negative EBITDA) (Net Debt 213.9m / EBITDA -139.1m)
Debt / FCF = -0.86 (negative FCF - burning cash) (Net Debt 213.9m / FCF TTM -249.7m)
Total Stockholder Equity = 89.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.60% (Net Income -196.4m / Total Assets 386.6m)
RoE = -220.1% (Net Income TTM -196.4m / Total Stockholder Equity 89.3m)
RoCE = -51.80% (EBIT -154.5m / Capital Employed (Equity 89.3m + L.T.Debt 209.0m))
RoIC = -36.24% (negative operating profit) (NOPAT -122.0m / Invested Capital 336.7m)
WACC = 13.13% (E(720.2m)/V(1.04b) * Re(14.35%) + D(319.4m)/V(1.04b) * Rd(13.13%) * (1-Tc(0.21)))
Discount Rate = 14.35% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 79.06 | Cagr: 6.79%
[DCF] Fair Price = unknown (Cash Flow -249.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.10 | # QB: 1
Revenue Correlation: 63.45 | Revenue CAGR: 25.29% | SUE: 1.16 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-1.27 | Chg30d=-3.58% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.43 | Chg30d=-21.47% | Revisions=+40% | GrowthEPS=+8.8% | GrowthRev=+0.9%
EPS next Year (2027-12-31): EPS=-2.31 | Chg30d=+10.21% | Revisions=+40% | GrowthEPS=+32.6% | GrowthRev=+49.6%
[Analyst] Revisions Ratio: +62% (up=5, down=0)